Hannah Valantine Sells Shares of BridgeBio Pharma
Hannah Valantine sold 2,808 shares of BridgeBio Pharma on June 22, as reported in recent filings.
Key Points
- Hannah Valantine sold 2,808 shares of BridgeBio Pharma on June 22, 2026.
- BridgeBio Pharma's stock traded near $68.63 on Thursday, with a market cap of $13.5 billion and a forward P/E ratio of 130.7.
- Analysts from Mizuho and Canaccord Genuity have maintained or initiated buy ratings with price targets up to $110.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Hannah Valantine, an insider at BridgeBio Pharma, Inc. (NasdaqGS: BBIO), sold 2,808 shares of the company on June 22, 2026. This transaction is part of recent insider activity reported for the biotechnology firm.
Insider Buying and Selling at BridgeBio Pharma, Inc.
In addition to Valantine's sale, other notable insider transactions include Jennifer Cook's planned sale of 21,967 shares at $70 on June 24, 2026, and Eric Aguiar's purchase of 3,990 shares on June 22, 2026. These transactions highlight ongoing insider activity within the company.
BridgeBio Pharma, Inc. Stock Down 10.4%
Shares of BridgeBio Pharma traded near $68.63 on Thursday. The company has a market cap of approximately $13.5 billion and a forward P/E ratio of 130.7, reflecting its valuation based on expected future earnings. The stock's 52-week range is between $41.30 and $84.94, and it has a beta of 0.975, indicating moderate volatility. The company's 50-day moving average is $69.67, and the 200-day moving average is $67.55.
$BBIO stock price
Daily closing prices, year to date. Not investment advice.
Other Institutional Activity in BridgeBio Pharma
Institutional investors have also been active in BridgeBio Pharma. BlackRock, Inc. reduced its holdings by 341,772 shares, ending with 14,207,757 shares valued at about $1.05 billion, representing a 2.3% decrease. Meanwhile, Janus Henderson Group PLC increased its position by 2,178,556 shares, totaling 13,179,013 shares worth approximately $978.6 million, marking a 19.8% increase. Viking Global Investors LP cut its stake by 2,551,500 shares to 11,842,434 shares, a 17.7% decrease. Farallon Capital Management LLC added 367,000 shares, bringing its total to 9,365,463 shares valued around $695.5 million, a 4.1% increase. Vanguard Portfolio Management LLC opened a new position with 8,080,573 shares valued at $600.1 million.
Analysts Set New Price Targets
Analysts have been active in setting new price targets for BridgeBio Pharma. On June 16, 2026, Mizuho maintained its buy rating with a $96 price target. Earlier, on June 3, Canaccord Genuity initiated coverage with a buy rating and a $104 target. Citigroup initiated a hold rating with an $82 target on May 19. Overall, the stock has a consensus strong buy recommendation with a mean price target of $102.28.
About BridgeBio Pharma
BridgeBio Pharma, Inc. is a biopharmaceutical company based in Palo Alto, California. It focuses on discovering, developing, and delivering medicines for patients with genetic diseases. Its portfolio includes treatments for cardiomyopathy, molybdenum cofactor deficiency, and achondroplasia, among others. The company was founded in 2015 and is led by CEO Dr. Neil Kumar.
Bottom Line
Hannah Valantine's recent sale of BridgeBio Pharma shares is part of ongoing insider activity at the company. Investors keep a close watch on such transactions as they can provide insights into insider sentiment. BridgeBio's stock performance and institutional activity are also key areas of interest, especially given the company's focus on genetic disease treatments and its current market valuation.
Get BridgeBio Pharma, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BBIO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.